By
AmyT on
March 31, 2010
Today, Sanofi-Aventis announced that it’s getting into the glucose meter manufacturing business, by partnering with a small company known for highly accurate meter technology, AgaMatrix (makers of WaveSense products, based on a patented electrochemistry formula).
Reports say the new Sanofi-branded meters will be out later this year, and that this move is part of a larger strategy to help Sanofi offer a “full diabetes management solution” — beyond its insulins, Lantus and Apidra, and the…
Read more »
By
AmyT on
December 7, 2009
How many diseases do you know of where patients are required to calculate exact dosing, up to half-a-dozen times a day, of a medicine so potent that mistakes could literally knock them out or kill them? I hate to be fatalistic, but after a few serious insulin flub-ups lately, I just can’t seem to get this thought out of my mind.
Of course we’re all just winging it. Carb-counting isn’t particularly exact, nor are our…
Read more »
By
AmyT on
November 17, 2009
Al Mann, CEO of MannKind Corp., is something of a legend in his own time. He not only founded MiniMed, acquired by Medtronic, but also four other successful medical companies. He’s a billionaire, with his own Biomedical Engineering Institute at the University of Southern California (USC), so we can assume that he’s not just championing the new inhalable insulin product Technosphere (brand name Afresa) as some kind of pipe dream or get-rich-quick scheme.
The guy…
Read more »
By
AmyT on
September 22, 2009
How many insulins have you tried? If you’re like most people, you only switch to something new when a better generation comes out, such as when Regular upgraded to Humalog or when NPH upgraded to Lantus. But when it comes to comparing insulin in the same family, say Humalog versus Novolog or Lantus versus Levemir, most of us only try something new when something goes very wrong, such as burning at the injection site. Yech……
Read more »
Considering what I am about to write, I feel a little guilty about the post headline here. But these sensational headlines are just the point: the media is abuzz the last few days with the possibility that Lantus insulin “may be linked” to cancer.
The rumors started late last week, when the media got wind that a prominent diabetes researcher forecasted that an “earthquake” event was about to hit that would compromise the safety profile…
Read more »
